44
FDA Expands Approval of Leniolisib for Pediatric Patients With APDS
Overview
The US Food and Drug Administration (FDA) has authorized the use of leniolisib (Joenja; Pharming) for children aged 4 to 11 years who weigh at least 27 kg and are diagnosed with activated phosphoinositide 3-kinase delta syndrome (APDS). APDS is a rare primary immunodeficiency disorder resulting from genetic variants in the PIK3CD or PIK3R1 genes. With this regulatory action, leniolisib becomes the first and only FDA-approved therapy available for this specific pediatric age group.
The FDA’s decision follows its acceptance of the supplemental new drug application in October 2025.
Clinical Perspectives
Eveline Wu, MD, MSCR, associate professor of pediatrics at the University of North Carolina at Chapel Hill, emphasized the clinical significance of shifting from symptom management to targeted therapy:
โPreviously, our best approach for children aged 4 to 11 years with APDS was to provide an accurate diagnosis and a treatment plan to manage the symptoms of APDS. With the approval of Joenja for this pediatric population, we can now take that support even further to address the underlying pathway of disease, with the goal of reducing symptoms and preventing the irreversible complications that often arise with APDS.โ
Vanessa Tenembaum, CEO of the Jeffrey Modell Foundation, highlighted the broader psychosocial impacts of this early intervention:
โAPDS is not a disease that waits. It can affect important aspects of childhood, potentially impacting time in school, time with friends, and other activities of daily life. This approval is a meaningful step forward because it gives younger patients and their physicians another much-needed option earlier in the disease journey.โ
Clinical Trial Efficacy
The approval was supported by data derived from a phase 3 clinical study. The trial demonstrated improvements in the underlying immune defects associated with APDS.
Table 1. Phase 3 Study Design and Efficacy Outcomes
| Study Parameter | Details |
| Trial Design | Phase 3, prospective, multicenter, open-label, single-arm study |
| Patient Population | 8 children, aged 4 to 11 years |
| Study Duration | 12 weeks |
| Efficacy Findings | Demonstrated reductions in lymphadenopathy Demonstrated a rise in naรฏve B cells |
Dosage and Administration
Leniolisib is administered as an oral tablet taken twice daily across all approved age groups, though specific dosages vary by patient weight and age. Pharming is actively seeking to expand access further, having submitted an additional supplemental new drug application on July 30 for children of lower body weights.
Table 2. Approved and Pending Leniolisib Dosing Regimens
| Age Group | Weight Criteria | Dosage |
| โฅ 12 years | Not specified | 70 mg twice daily (Originally approved in March 2023) |
| 4 to 11 years | โฅ 27 kg | 40 mg, 50 mg, or 70 mg twice daily (Dependent on weight) |
| Children | 13 kg to < 27 kg | Application submitted; pending FDA review |
Safety Profile and Contraindications
Throughout the clinical study, treatment-emergent adverse events were reported as mild to moderate in severity. The FDA identified the following eight most common side effects associated with leniolisib:
- Stomach pain
- Respiratory tract infection
- Diarrhea
- Headache
- Cough
- Nausea
- Rhinitis
- Alopecia
Additionally, the FDA advised that leniolisib should not be used in patients presenting with moderate to severe liver impairment.
